POTE ankyrin domain family member GGenealiases: A26C2 · ACTBL1 · CT104.4 · POTE-14 · POTE14 · POTE14alpha
Q-omics provides the consensus-scored POTEG profile across patient tissues and cancer cell-line models. POTEG expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, POTEG is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, POTEG RNA expression shows 8,557 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where POTEG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEG survival associations across molecular data types. POTEG RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEG RNA expression–survival associations across cancer types. High POTEG expression shows unfavorable associations in ACC, UVM, BLCA, KICH and LUAD, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for POTEG RNA expression.
This table summarizes POTEG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for POTEG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEG shows lower tumor expression in PAAD and higher tumor expression in HNSC, BRCA, LIHC, PRAD and ESCA. The HNSC box plot shows higher POTEG RNA expression in tumor versus normal tissue (log2 FC = +0.046, t-test p = .001).
This table shows molecular features associated with POTEG in patient tissues and cancer cell lines. In patient samples, POTEG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
